Novartis To Increase Marketing Support As New Products Drive Growth In The Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis highlights its under-appreciated new product portfolio as total sales increase by 1% in the second quarter, buffeted by adverse currency movements, generic competition to Diovan and enoxaparin, and manufacturing issues.